


Connecticut
Urology
Society

Connecticut Urology Society
Annual Educational Meeting
Wednesday, November 15, 2023
8:00 am - 4:30 pm
Program



UROLOGY EXHIBITORS

Platinum

Boston Scientific
Endo Pharmaceuticals
Lantheus
Myriad Genetic

Gold

Bayer
Procept BioRobotics
Sunitomo Pharma - Womens Division
Sunitomo Pharma - Myovant

Silver

AbbVie Pharmaceuticals
Alnylam Pharmaceuticals, Inc.
BD Becton, Dickinson and Company
Calyxo
Community Health Network
Connecticut State Medical Society
Cook Medical
Exsome Diagnostics
Irrimax Corp. - Irrisept
Janssen Oncology
Karl Storz
Laborie Medical
Pfizer
Teleflex Interventional Urology

Mission Statement

The mission statement of the Connecticut Urology Society is to serve, represent and advance the science and the ethical practice of Urology in the State of Connecticut. Our target audience includes urologists and their staff, including, nurses, PAs, medical assistants, scribes, office managers and front office staff.

The Society promotes excellence in patient care and education in Urology through the sponsorship of an Annual Scientific meeting.

The Connecticut Urology Society is dedicated to providing communication and fellowship to the members of the Urologic Community in Connecticut through these meetings.

The programs are an opportunity for urologists to identify and discuss critical issues facing their profession and are designed to meet the clinical and educational needs of its members and the objectives set forth by the CT Urology Executive Board. Specific competency, performance and patient outcomes will be proposed by speakers and evaluated by participants.

(approved 10/11/18 Executive Committee)

8:00 **Registration**

8:10 **Opening Remarks** – Timothy Siegrist, MD,
President

8:15 **Business Meeting**

8:30 **Product Theater – “Aquablation for BPH”**
– Ravi Munver, MD

9:15 **Multiparametric MRI, Targeted Biopsy and
Molecular Diagnostics – Emerging Tools
and Challenges in Modern Prostate
Cancer Diagnosis and Treatment**
– James Wysock, MD

Objectives: 1. Review the role of novel biomarkers and MRI for prostate cancer risk stratification and biopsy decision. 2. Review targeted biopsy techniques and approaches. 3. Review molecular diagnostic imaging and role for disease localization and staging.

10:00 **Breakfast of Champions in Vendor Hall**

10:30 **Product Theater “Prolaris Utility
and New ARR Enhancement”**
– Rob Finch, M.S., CGC, Director, Urology
Medical Affairs - Myriad Genetic Laboratories

11:00 **Energy Sources and Approaches for Partial
Gland Prostate Ablation**
– James Wysock, MD

Objectives: 1. Define and review rationale for partial gland ablation including Index Lesion Hypothesis, MR visible disease. 2. Review available tools for partial

gland ablation. 3. Review current evidence supporting partial gland ablation treatment approaches for clinically localized prostate cancer.

11:45 Yale Research - Findings in 2023

– Preston Sprenkle, MD

Objectives: 1. Appreciate research achievements in benign and malignant urology completed at Yale. 2. Increase awareness of ongoing clinical trials available for urology patients in Connecticut.

12:15 Healthy Choice Lunch in Vendor Expo

**12:45 Product Theater - “Pylarify
PET/CT in Prostate Cancer
Patients Combining the Accuracy of PET
Imaging, the Precision of PSMA Targeting,
and the Clarity of an 18F Radioisotope”**

– Gary Ulaner, MD, PhD, FACNM

**1:30 Hartford HealthCare Research – Findings in
2023**

– Joseph Wagner, MD

Objectives: 1. Understand the pros and cons of transperineal versus transrectal prostate biopsies. 2. Cite relevant literature concerning the prevention of lymphocele during radical prostatectomy.

**2:00 Little Incisions, Big Changes: Minimally
Invasive Urologic Reconstruction**

– Joshua Sterling, MD

Objective: Identify key elements in the evaluation for upper tract urinary strictures, effect improved outcomes in upper tract urinary strictures.

2:30 Advocacy – Why Urologists Should Engage

– *Senator Saud Anwar, MD*

Objectives: 1. To describe the political climate and how it is affecting the practice of medicine. 2. To highlight some of the proactive legislation passed in 2022 and 2023 addressing prior authorization. 3. Step therapy and protecting the practice of medicine.

3:10 Coffee Break

3:30 The Cost of Healthcare – Facts and Myths and How it Affects the Practice of Medicine

– *Wendy L. Kroll, JD*

Objectives: 1. To discuss the effect of private equity arrangements on the cost of healthcare and the corporate practice of medicine. 2. To review contract terms that have a direct impact on patient quality of care.

4:00 Brief Medical Practice Legal Update: Patient Record Destruction and the Law – The Risk of Treating Family and Friends – What's at Stake

– *Joyce A. Lagnese, JD*

Objectives: This brief presentation will discuss destruction of patient medical records as well as the identification of issues associated with texting, emailing and personal devices. 1. To review the current laws surrounding the treatment of family and friends. 2. To review protocols offices should have in place when writing prescriptions. 3. Review penalties and risks involved in violating state law.

4:30 Certificates and Door Prizes

“This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Connecticut Society of Eye Physicians and CT Urology Society. The Connecticut Society of Eye Physicians is accredited by the ACCME to provide continuing medical education for physicians.”

CSEP designates this educational activity for a maximum of 4.0 AMA PRA Category I Credit(s)TM toward the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she spent in the activity.

CSEP ensures that all decisions related to the planning, faculty selection, delivery, and evaluation of accredited education are made without any influence or involvement from the owners and employees of an ineligible company. In addition, CSEP ensures that the Accredited education is free of marketing or sales of products or services and that all faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. CSEP will not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.

FACULTY



Senator Saud Anwar, MD

State Senator Saud Anwar was first elected to the Senate in February 2019 to represent the residents of the 3rd State Senate District towns of East Hartford, East Windsor, Ellington and South Windsor.

Saud was first elected to public office in 2011 as a member of South Windsor's Town Council. He has served two terms as South Windsor mayor, once from 2013 to 2015 and once from 2017 to 2019.

Saud is a medical doctor with specializations in treating lung diseases and critical care medicine, occupational and environmental medicine. He currently serves as Chair of the Department of Internal Medicine at Manchester Memorial and Rockville General Hospitals. Saud was trained in pulmonary and critical care medicine at, and holds a Master's Degree in Public Health from, Yale University.

Saud also works with humanitarian and peace initiatives on a local, national and global scale. He has organized medical missions for disaster relief, receiving citations for doing so from former Governor Jodi Rell, United States Senator Richard Blumenthal and Lieutenant Governor Susan Bysiewicz.

Wendy L. Kroll, JD

Wendy L. Kroll is a health care attorney well versed in health care operations from both a business and regulatory perspective. Her experience in virtually all aspects of health care delivery in commercial and government payor markets has provided her with an in-depth knowledge to structure successful mergers, acquisitions and other business transactions for provider entities of all types, negotiate arrangements with payors, and develop new health care delivery models that match entrepreneurial

innovation with the highly complex compliance environment. Wendy has significant experience working for Fortune 100 healthcare companies and representing health care providers in all aspects of federal regulation (and their state counterparts), including Stark, Anti-kickback, HIPAA and the full array of other fraud and abuse laws. Wendy maintains a client-supportive presence in legislative and regulatory forums as part of her commitment to advocating for health care providers and patients to help ensure the integrity and stability of our health care system.



Joyce A. Lagnese

Ms. Lagnese is one of the founding principals of the Hartford Law firm of Danaher Lagnese, PC, where she serves as head of the Medical Malpractice Defense Unit. She is a high honors graduate from the State University of New York and obtained her law degree with honors in 1980 from Hofstra University School of Law. Her practice concentration is high exposure medical practice defense litigation. For over three decades, she has defended medical malpractice cases throughout Connecticut on behalf of physicians from every medical specialty, and has successfully tried to verdict a large number of medical malpractice cases including claims of wrongful death and permanent injury. Her practice also includes representation of medical practitioners and institutions in administrative proceedings before the Connecticut Department of Public Health.

Ms. Lagnese has been an invited lecturer and Keynote

Speaker to various local and regional medical societies, physicians organizations and hospitals on medico-legal topics and is co-author of a textbook on Connecticut Medical Malpractice. She has also been an advocate in the Connecticut State Legislature for malpractice tort reform.



Preston Sprenkle, MD

Dr. Preston C. Sprenkle is an Associate Professor of Urology at Yale, Co-chair Cancer Liason Committee - Oncology; Co-chair, NCCN Guidelines Committee on Prostate Cancer Early Detection; Co-Division Chief, Division of Urology at VA Connecticut Healthcare System. Dr. Sprenkle completed his medical school training at Columbia, followed by a residency at New York Presbyterian Hospital and a fellowship at Memorial Sloane Kettering Cancer Center. At Yale he specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma.



Joshua Sterling, MD

Dr. Sterling is an Assistant Professor of Urology specializing in trauma and genitourinary reconstruction at Yale School of Medicine. He completed a GURS fellowship in Reconstructive Urology and Transgender Care at SUNY Upstate Medical University. He earned his medical degree from New York Medical College and completed his

urologic residency at Robert Wood Johnson University Hospital. Dr. Sterling's clinical areas of interest are urethral and ureteral strictures, genitourinary fistulae, urinary complications of radiation, and genital gender affirming surgery. His research interests focus on stricture formation, tissue regeneration, and the effect of sex and gender on health care outcomes. He is the author of over 50 peer-reviewed manuscripts and book chapters and is a co-author of the American Urologic Association core curriculum on Gender Affirming Surgery.



Joseph Wagner, MD

Dr. Joseph Wagner has served as the Director of Robotic Surgery of Hartford Healthcare since 2003 and is currently the Chairman of the Department of Urology at Hartford Hospital. After graduating from Amherst College and the University of Connecticut School of Medicine, Dr. Joseph Wagner performed his surgical and urological residency training at Boston University. He went on to the National Cancer Institute for his urologic oncology fellowship and became the Physician In Charge of Urologic Oncology at Beth Israel Medical Center in New York City in 1997. In 2001, Dr. Wagner performed some of the first robotic urologic surgeries in the United States. He has published numerous peer reviewed manuscripts and abstracts along with several book chapters.



James Wysock, MD, MS

Dr. Wysock, is an Assistant Professor of Urology at NYU School of Medicine with a clinical practice focused on urologic oncology. He obtained his medical degree from Northwestern University Feinberg School of Medicine and completed his residency training at New York Presbyterian Hospital/Weill Cornell Medical College. He also completed fellowship training at NYU focusing on robotic surgery and urologic oncology. His clinical and research efforts center on providing advanced diagnostic and treatment strategies across the breadth of urologic malignancies. He has extensive experience in image-guided prostate cancer management (MRI-US fusion prostate biopsy, transperineal prostate biopsy, and prostate ablation) as well as robotic surgical techniques and management of multi-disciplinary oncology practice teams.

Pre-Competency Questions

Physician's Name _____

Little Incisions, Big Changes: Minimally Invasive Urologic Reconstruction – *Joshua Sterling, MD*

Question 1. The success of endoscopic management for ureteral strictures significantly worsens in strictures that are:

- a. <0.5 cm
- b. >1 cm

- c. >2 cm
- d. >5 cm

Question 2. Adverse events related to the injection of mitomycin C include:

- a. Osteitis pubis, rectourethral fistula formation, bladder necrosis
- b. Hematuria, dysuria
- c. Bladder neck contracture
- d. Mitomycin C is not associated with any serious adverse events

Hartford HealthCare Research – Findings in 2023

– *Joseph Wagner, MD*

Question 1. Which of the following appears to be the most successful in preventing lymphoceles after radical prostatectomy?

- a. Liberal use of clips
- b. Hemostatic agents
- c. Liberal use of cautery
- d. A and C
- e. Peritoneal flap

Question 2. Which of the following yields the highest rate of detecting clinically significant prostate cancer?

- a. Transperineal fusion biopsy with grid
- b. Transrectal fusion biopsy
- c. Transperineal fusion biopsy with precision point
- d. All are equal
- e. A and C

Multiparametric MRI, Targeted Biopsy and Molecular Diagnostics – Emerging Tools and Challenges in Modern Prostate Cancer Diagnosis and Treatment

– *James Wysock, MD*

Question 1. Which of the following is the next best test for a 65 year old healthy man that is referred with a PSA of 7 ng/mL and a prostate MRI demonstrating a PI RADS 3 lesion?

- a. ConfirmMDx
- b. PSMA PET CT
- c. ExactVue MicroUS
- d. Decipher Biopsy
- e. ExoDx Prostate Test

Question 2. What is the recommended next step for a 65 year old healthy man with a family history of prostate cancer, PSA of 7 ng/mL, 4Kscore 20%, prostate volume of 30 cc, 4 x 5 mm PI RADS 4 lesion in the anterior base with a negative transrectal prostate biopsy in both systematic and targeted biopsy cores?

- a. Repeat MRI prostate
- b. PMSA PET CT
- c. Repeat prostate biopsy
- d. Genetic testing
- e. MDx Genomic Prostate Score

Energy Sources and Approaches for Partial Gland Prostate Ablation – *James Wysock, MD*

Question 1. Transrectal High Intensity Focused Ultrasound (HIFU) prostate ablation utilizes the following to

determine real-time treatment success?

- a. Rectal wall temperature
- b. Changes in ultrasound grey-scale appearance
- c. Color Doppler Sonography
- d. Contrast enhanced ultrasound
- e. B & D
- f. All of the above

Question 2. A 75M diagnosed with GG2, MR concordant prostate cancer in the right posterolateral midgland elects to proceed with prostate cryoablation. Which of the following is the most important feature to consider in treatment planning?

- a. Prostate volume
- b. Presence of intraprostatic calcifications
- c. PI RADS score
- d. MDx Genomic Prostate Score
- e. MRI Lesion size

Outcome Measurements

1. Has this program changed the way you will care for patients? Yes No
2. How has this program changed the way you will care for patients?

3. Do you believe this program will have a positive effect on patient surgical or clinical outcomes?
 Yes No
4. Can you offer other speakers or talks that will provide information to improve clinical outcomes at the next meeting? Yes No

Officers

- President – Tim Siegrist, M.D.
President Elect – Guy Mannetti, M.D.
Secretary – Jared Bieniek, M.D.
Immediate Past President – Joseph Wagner, M.D.
Treasurer – Michael Fasulo, M.D.

Executive Committee Members

- Milton Armm, M.D.
Thomas Buckley, M.D.
Stuart Kesler, M.D.

Product Theater Speakers

“PROLARIS: Using Genomic Information to Help Make ADT Decisions”

– *Rob Finch, M.S., CGC*, Director, Urology Medical Affairs - Myriad Genetic Laboratories

Rob Finch is a Certified Genetic Counselor. He graduated with a Masters Degree in Human Genetics from the University of Pittsburgh in May 2001. Rob worked at Memorial Sloan-Kettering Cancer Center from May 2001 to September 2003, where he headed up the Hereditary Colorectal Cancer Registry, as well as provided risk assessment and genetic testing to patients through the Clinical Genetics Service. In September 2003, Rob joined the Myriad Genetics Team, where he has served as a Regional Medical Specialist and Institutional Account Executive for the Oncology Division, Medical Science Liaison for the Urology Division and currently serves as Director of Urology Medical Affairs. Rob works to educate and support healthcare providers who treat prostate cancer for Myriad’s Hereditary Cancer Germline Testing, Precise Tumor Somatic Testing and Prolaris, a biomarker to assess the aggressiveness of prostate cancer.



“Aquablation for BPH”

– *Ravi Munver, MD*

Dr. Ravi Munver has been performing the Aquablation Therapy procedure for men with BPH since May of 2022, and has completed over 60 cases since then. He championed the program and was the first to bring the Aquablation Therapy Technology to Hackensack University Medical Center. Dr. Munver also holds the titles of Vice Chair for the Department of Urology and Division Director of Minimally Invasive & Robotic Urologic

Surgery as well as Chief of Living Donor Kidney Surgery at Hackensack University Medical Center in Hackensack, New Jersey.

Dr. Munver completed Medical School at Weill Medical College of Cornell University, his Residency at Duke University Medical Center, completed his undergraduate degree at Cornell University, College of Arts and Sciences and his Fellowship New York Presbyterian – Weill Cornell Medical center.

“Pylarify PET/CT in Prostate Cancer Patients Combining the Accuracy of PET Imaging, the Precision of PSMA Targeting, and the Clarity of an 18F Radioisotope”

– *Gary Ulaner, MD, PhD, FACNM*

Gary Ulaner, MD, PhD, FACNM, is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy (MIT) at the Hoag Family Cancer Institute and a Professor of Radiology and Translational Genomics at the University of Southern California. He obtained his MD and PhD in Cancer Biology at Stanford University School of Medicine, then completed residencies in Nuclear Medicine and Diagnostic Radiology at the University of Southern California.

Dr. Ulaner has been the principal investigator of prospective clinical trials for 6 novel PET radiotracers for patients with breast cancer, prostate cancer and myeloma, funded by 2 National Institutes of Health R01s and grants from the Department of Defense (DoD). His research emphasizes targeted imaging to guide targeted therapy of cancer, with an emphasis on estrogen receptor, human epidermal growth factor 2 (HER2), prostate-specific membrane antigen (PSMA), and CD38-targeted PET imaging.

SAVE THE DATE
Thursday
November 14, 2024

Connecticut Urology
Annual Scientific Program

At the Aqua Turf Club
556 Mulberry Street
Plantsville, CT